Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (11,604,778)	$ (5,661,230)
Adjustments to reconcile net loss to net cash used in operating activities:
Acquired in-process research and development	3,031,226	0
Goodwill impairment	3,283,379	0
Depreciation	3,366	12,540
Amortization of right of use asset	16,629	0
Gain on sale of property and equipment	(2,000)	(15,437)
Share-based expense	683,104	1,123,000
Issuance of warrants in connection with reverse stock split	63,536	0
Vendor share-based expense	47,427	52,281
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(297,712)	(310,239)
Accounts payable, accrued expenses and other liabilities	54,171	(623,992)
Net cash used in operating activities	(4,721,652)	(5,423,077)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of property and equipment	2,000	22,500
Net cash provided by investing activities	2,000	22,500
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock and warrants in public offering	13,421,950	0
Net proceeds from issuance of common stock and warrants in registered direct offering	2,699,050	0
Proceeds from exercise of warrants	5,009	1,480,000
Net cash provided by financing activities	16,126,009	1,480,000
Net change in cash and restricted cash	11,406,357	(3,920,577)
Cash and restricted cash at beginning of period	638,115	5,599,572
Cash and restricted cash at end of period	12,044,472	1,678,995
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	8	599
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Right of use asset acquired in exchange for lease liability	43,330	0
Issuance of common stock to vendor	7	0
Issuance of common stock to acquire in-process research and development	3,031,226	0
Issuance of common stock to adjust for Reverse Stock Split	1	0
Issuance of common stock from cashless exercise of purchase warrants	1,890	0
Conversion of Series B preferred stock to common stock	$ 0	$ 316